chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 15.0
Sex: F
Vaccine: HPV4, TDAP, HPV4, TDAP
Symptoms: Pain in extremity
Clinical narrative: Approx 36 hours after received 1st HPV and TDAP (had had 5 prior DTAP) pt had severe pain from waist down to feet. Pt then felt a somewhat tired and weak overall and laid in bed much of day but could walk normally. Then 48-72 hours after vaccines received, pt developed upper stomach ache and nausea. She was still somewhat tired but leg pain and weak feeling in legs resolved.
Age: 37.0
Sex: F
Vaccine: HEP, HEP
Symptoms: Uveitis
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #17 of 32, a 37 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 37 year old female on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. Seven days after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced influenza-like symptoms. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327 to WAES # 1004USA02341, WAES # 1004USA02343 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 37.0
Sex: F
Vaccine: HEP, HEP
Symptoms: Influenza like illness, Uveitis
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #17 of 32, a 37 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 37 year old female on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. Seven days after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced influenza-like symptoms. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327 to WAES # 1004USA02341, WAES # 1004USA02343 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 0.36
Sex: F
Vaccine: DTAPIPVHIB, PNC
Symptoms: Diarrhoea, Vomiting
Clinical narrative: Vomiting/Diarrhea
Age: 34.0
Sex: F
Vaccine: FLU(H1N1)
Symptoms: Headache, Myalgia, Neck pain
Clinical narrative: 04/19/2010 Complaint of muscle pain throughout upper arm and radiated up neck and head.
Age: 37.0
Sex: M
Vaccine: PPV
Symptoms: Erythema, Myalgia, Oedema peripheral, Skin warm
Clinical narrative: swelling of arm, large red patch (2"x3"), severe muscle ache, arm hot to the touch.  Doctor prescribed METHYLPREDNISOLONE 4 MG DOSEPK.
Age: 4.0
Sex: F
Vaccine: DTAPIPV, MMR, VARCEL, FLU3
Symptoms: Injection site cellulitis, Injection site erythema, Injection site induration, Injection site mass, Injection site pain
Clinical narrative: Child received VARIVAX, MMR, and KINRIX vaccine on 4-13-10 - came back in to office 4-16-10 with approximately 8cm x 7cm circular, erythemic hardened knot to left leg. Painful to touch. Child Dx with left leg cellulitis and Tx with OMNICEF 250mg/5mL-3 mL PO BID x 10 days with F/U in 1 week.
Age: 4.0
Sex: F
Vaccine: DTAPIPV, MMR, VARCEL, FLU3
Symptoms: Injection site erythema
Clinical narrative: Child received VARIVAX, MMR, and KINRIX vaccine on 4-13-10 - came back in to office 4-16-10 with approximately 8cm x 7cm circular, erythemic hardened knot to left leg. Painful to touch. Child Dx with left leg cellulitis and Tx with OMNICEF 250mg/5mL-3 mL PO BID x 10 days with F/U in 1 week.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Angiogram pulmonary normal, Basophil count decreased, Basophil percentage decreased, Blood creatine phosphokinase MB increased, Blood creatine phosphokinase normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: C-reactive protein increased, Chest X-ray normal, Chest discomfort, Chest pain, Computerised tomogram normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Differential white blood cell count, Dyspnoea, Echocardiogram normal, Eosinophil count decreased, Eosinophil count normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Haematocrit normal, Haemoglobin normal, Headache, Laboratory test abnormal, Lymphocyte count normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Lymphocyte percentage decreased, Mean cell haemoglobin concentration normal, Mean cell haemoglobin increased, Mean cell volume normal, Mean platelet volume decreased
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Monocyte count increased, Monocyte percentage increased, Neutrophil count normal, Neutrophil percentage, Platelet count normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Pyrexia, Red blood cell count normal, Red blood cell sedimentation rate normal, Red cell distribution width normal, Troponin T
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Troponin increased, White blood cell count normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Basophil percentage decreased, Blood creatine phosphokinase MB increased, C-reactive protein increased, Chest pain, Dyspnoea
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Eosinophil count decreased, Haematocrit normal, Haemoglobin normal, Headache, Lymphocyte percentage decreased
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Mean cell volume normal, Mean platelet volume decreased, Monocyte percentage increased, Pyrexia, Red blood cell count normal
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 20.0
Sex: M
Vaccine: ANTH, SMALL, ANTH, SMALL, ANTH, SMALL, SMALL
Symptoms: Echocardiogram normal, Electrocardiogram abnormal, Myocarditis, Troponin I increased
Clinical narrative: SM woke up with chest pain, headache, fever and trouble deep breathing due to pain in chest. Was vaccinated on 4/7/10 with SPV and AVA.
Age: 11.0
Sex: M
Vaccine: MNQ, TDAP, VARCEL
Symptoms: Bordetella test positive, Pertussis
Clinical narrative: Patient was diagnosed with pertussis 3/10 despite receiving Tdap vaccine 1/08.
Age: 67.0
Sex: M
Vaccine: PPV
Symptoms: Arthralgia, Chest pain, Dizziness, Flushing, Headache
Clinical narrative: Hives & swelling left arm, tinnitus - extreme, crippling pain in knees & joints, dizziness, headaches, sweating, thirst, excessive urination, sore feet, sore heels, mood changes, fever, facial flushing, chest pains, arm pains, muscle pain, vision change.
Age: 67.0
Sex: M
Vaccine: PPV
Symptoms: Hyperhidrosis, Mood altered, Myalgia, Oedema peripheral, Pain in extremity
Clinical narrative: Hives & swelling left arm, tinnitus - extreme, crippling pain in knees & joints, dizziness, headaches, sweating, thirst, excessive urination, sore feet, sore heels, mood changes, fever, facial flushing, chest pains, arm pains, muscle pain, vision change.
Age: 67.0
Sex: M
Vaccine: PPV
Symptoms: Pollakiuria, Pyrexia, Thirst, Tinnitus, Urticaria
Clinical narrative: Hives & swelling left arm, tinnitus - extreme, crippling pain in knees & joints, dizziness, headaches, sweating, thirst, excessive urination, sore feet, sore heels, mood changes, fever, facial flushing, chest pains, arm pains, muscle pain, vision change.
Age: 67.0
Sex: M
Vaccine: PPV
Symptoms: Visual impairment
Clinical narrative: Hives & swelling left arm, tinnitus - extreme, crippling pain in knees & joints, dizziness, headaches, sweating, thirst, excessive urination, sore feet, sore heels, mood changes, fever, facial flushing, chest pains, arm pains, muscle pain, vision change.
Age: 22.0
Sex: M
Vaccine: VARCEL
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth
Clinical narrative: Had a large mass surrounding injection site that appeared 24 hr after injection, large reddened area and warm to the touch. Mass was painful and was there for about 3 days.
Age: 22.0
Sex: F
Vaccine: VARCEL
Symptoms: Injection site erythema, Injection site induration, Injection site pain, Injection site swelling
Clinical narrative: 24 hr after shot, got 1 X 1 inch red, raised area.  36 hr after shot, redness was lighter & more diffuse - 3 X 3 inch area, swelling and tenderness and hard area where shot was given.  A week after, it still looks like a line.
Age: 29.0
Sex: F
Vaccine: VARCEL
Symptoms: Injection site swelling
Clinical narrative: 3in x 4in swelling at injection site.
Age: 37.0
Sex: F
Vaccine: PPV
Symptoms: Body temperature normal, Erythema, Pain in extremity, Pruritus, Skin warm
Clinical narrative: Patient received pneumococcal vaccine in right upper arm 4/12/2010. Later same day her arm began to hurt. On 4/13/2010 her arm was red, hot, itchy temp of 99.3 patient evaluated by PA in clinic on 4/15/2010. Prescription for MEDROL- DOSEPAK ordered.
Age: 4.0
Sex: M
Vaccine: DTAP, HEP, IPV, MMR
Symptoms: Oedema peripheral, Skin reaction, Tenderness
Clinical narrative: Swelling, tenderness locally in right arm where 3 vaccines given.
Age: 35.0
Sex: M
Vaccine: ANTH, FLU3
Symptoms: Burning sensation, Induration, Inflammation, Injection site erythema, Pain
Clinical narrative: 2 days after shot continuing soreness and burning. Itching and inflamed. Warm and hard to touch. Excessive redness around shot area.
Age: 35.0
Sex: M
Vaccine: ANTH, FLU3
Symptoms: Pruritus, Skin warm
Clinical narrative: 2 days after shot continuing soreness and burning. Itching and inflamed. Warm and hard to touch. Excessive redness around shot area.
Age: 1.3
Sex: M
Vaccine: DTAPIPVHIB
Symptoms: Blood test, Skin discolouration, Staring
Clinical narrative: Episode of staring & duskiness.  Called 911 and taken to ER.
Age: 5.0
Sex: M
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site swelling, Injection site urticaria
Clinical narrative: Redness and swelling from elbow to shoulder 14 cm long. 4 cm x 5 cm welt area at site of injection. Afebrile.
Age: 5.0
Sex: F
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus
Clinical narrative: On 4-7-10 child received DTAP in left thigh, IPV in right thigh, MMR left arm, VARIVAX right arm. Evening of 4-8-10 Mom noticed reddened area on right arm, C/O itching, some pain. Seen AM on 4-9-10. Treat with cool compresses. Monitor for worsening.
Age: 65.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site haematoma, Injection site pain
Clinical narrative: Patient reports significant bruising and pain at injection site. Pain has persisted for 3 1/2 months. Initially pain was continual, now occurs to R deltoid intermittently several times weekly.
Age: 2.0
Sex: M
Vaccine: MMR, VARCEL
Symptoms: Asthma, Dyspnoea, Rash
Clinical narrative: Mother states that she feels that the following is related to the vaccines. Child woke in the middle of the night unable to breathe. An ambulance was called & taken to ER. Diagnosis - Asthma. Mother states he had developed a rash on his back; front of trunk - 1-2 days before the asthma attack.
Age: 2.0
Sex: F
Vaccine: HEPA
Symptoms: Coxsackie viral infection, Culture urine positive, Febrile convulsion, Pharyngeal lesion, Rash vesicular
Clinical narrative: Febrile seizure - given anti-pyretics. On exam- oropharynx lesions seen - vesicular, consistent with coxsackie virus.
Age: 2.0
Sex: F
Vaccine: HEPA
Symptoms: Urine analysis normal
Clinical narrative: Febrile seizure - given anti-pyretics. On exam- oropharynx lesions seen - vesicular, consistent with coxsackie virus.
Age: 37.0
Sex: F
Vaccine: TDAP
Symptoms: Unevaluable event
Clinical narrative: None stated
Age: 25.0
Sex: F
Vaccine: HEPA, TDAP
Symptoms: Loss of consciousness, Pallor, Posture abnormal, Respiratory depression, Unresponsive to stimuli
Clinical narrative: Receiving 2nd of 6 requested vaccines, had LOC 30-45 seconds.  Non-responsive to verbal/tactile stimuli, extremely pale, slumped in chair, minimal resp. effort.  911 called.  Regained consciousness by their arrival & was PO hydrating & VS monitored (BP 100/70, HR 110).  Given choice by EMT & chose to go to ED.
Age: 5.0
Sex: M
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Left upper thigh red, swollen, warm & tender to touch. Area measures 11 1/2 cm x 10 1/2 cm. Rx for KEFLEX 250/5 ml 3 tsp BID x 7 d & BENADRYL.
Age: 73.0
Sex: F
Vaccine: PPV
Symptoms: Asthenia, Dizziness, Heart rate increased
Clinical narrative: Patient called on 4-14-10 and stated she felt weak, dizzy, and her heart was beating very fast on 4-13-10. She stated it was hours after her pneumonia shot.
Age: 1.01
Sex: M
Vaccine: HEPA, MMR, PNC
Symptoms: Inappropriate schedule of drug administration, Unevaluable event
Clinical narrative: None stated.
Age: 1.01
Sex: M
Vaccine: HEPA, HIBV, PNC
Symptoms: Wrong drug administered
Clinical narrative: pt was due for HIB injection but was given Hiberix
Age: 0.5
Sex: M
Vaccine: DTAP
Symptoms: Cerebrovascular accident, Convulsion, Hemiparesis, Lumbar puncture, Nuclear magnetic resonance imaging brain abnormal
Clinical narrative: sent to emergency room due to left sided weakness, had a seizure upon arrival to er---MRI/MRA revealed Right MCA stroke.
Age: 0.5
Sex: M
Vaccine: DTAP
Symptoms: Scan brain
Clinical narrative: sent to emergency room due to left sided weakness, had a seizure upon arrival to er---MRI/MRA revealed Right MCA stroke.
Age: 0.19
Sex: M
Vaccine: DTAPIPVHIB
Symptoms: Crying, Immunisation reaction, Injection site erythema, Injection site swelling, Irritability
Clinical narrative: Patient with local swelling and redness at the site of the injection. Injection given on left upper thigh. Patient with fussiness and crying per mom since the injection was given. Able to be consoled but when injection site touched patient cries. Acetaminophen 80mg given PO. Ice pack applied. Home management advice given per protocol on immunization reaction. Dr aware and also assessed site.
Age: 4.0
Sex: U
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Erythema, Nodule
Clinical narrative: 24-36 hours after Dtap (L thigh) Pt developed red knot and spreading out. No fever, no pain. Pt able to walk and jump, no warmth noted.
Age: 11.0
Sex: F
Vaccine: HEPA, HPV4, MNQ, VARCEL
Symptoms: Dizziness, Headache, Injection site pain, Myalgia, Pyrexia
Clinical narrative: 4-6-10 - Pt c/o feeling dizzy after imm. Pt went bike riding after lunch for most a day. During evening (R) leg muscle was achy - 6 days in duration. Pt also c/o headache 4/7 and 4/8 pt treated with TYLENOL. Pt states that she "collapsed" 4/7 but was able to stand up - (L) arm sore at site of injection - 4/12/10 febrile 24 hrs.
Age: 11.0
Sex: F
Vaccine: HEPA, HPV4, MNQ, VARCEL
Symptoms: Syncope
Clinical narrative: 4-6-10 - Pt c/o feeling dizzy after imm. Pt went bike riding after lunch for most a day. During evening (R) leg muscle was achy - 6 days in duration. Pt also c/o headache 4/7 and 4/8 pt treated with TYLENOL. Pt states that she "collapsed" 4/7 but was able to stand up - (L) arm sore at site of injection - 4/12/10 febrile 24 hrs.
Age: 18.0
Sex: M
Vaccine: FLUX(H1N1)
Symptoms: Stereotypy
Clinical narrative: Increase in stereotypics @ this time after H1N1 injection also tapering off risperdal probable cause of increase stereotypics. Unable to get vaccine information given by the health department.  We did not administer the vaccine.
Age: 36.0
Sex: F
Vaccine: HEPAB, TDAP
Symptoms: Laboratory test, Neuralgia, Nuclear magnetic resonance imaging
Clinical narrative: 1 wk after vaccination - moving nerve pain on arms, legs, neck. No loss of function. Pursuing treatment with private physician.
Age: 40.0
Sex: F
Vaccine: HEPAB, TDAP
Symptoms: Urticaria
Clinical narrative: Hives - no medical treatment.
Age: 0.44
Sex: F
Vaccine: DTAPIPVHIB, PNC, RV5
Symptoms: Rash erythematous, Rash maculo-papular
Clinical narrative: Pt has an erythematous maculopapular rash according to the ER report. She was treated with diphenhydramine 6.25mg once, prednisolone 3mg/mL (6mg once), and ranitidine 15mg once. She was discharged with Rx for BENADRYL and ORAPRED.
Age: 3.0
Sex: M
Vaccine: PNC13
Symptoms: Injection site erythema, Injection site induration, Injection site mass, Injection site swelling, Injection site warmth
Clinical narrative: Warm, red area around immunization site. Next morning, swelling and redness decreased leaving hard lump in upper (R) arm. No pain, or limitation.
Age: 5.0
Sex: M
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site pain, Injection site rash, Injection site swelling, Pyrexia
Clinical narrative: Raised red rash to right thigh.  Low grade fever & soreness to injection site March 1-3; Noticed rash to thigh March 6.
Age: 4.0
Sex: M
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Blood culture negative, Full blood count, Injection site swelling, Injection site warmth, Pyrexia
Clinical narrative: Swelling and heat to (L) deltoid 1800 4/16. Took to ER 2200 pm, blood work obtained; IV Clindamycin given given as fever 100.6. 11:30 pm transferred to hospital. Admitted 48 hours with IVF and antibiotics. No fever since. Home on PO Clindamycin.
Age: 0.17
Sex: M
Vaccine: DTAPIPVHIB, HEP, PNC, RV5
Symptoms: Crying, Depressed level of consciousness, Grunting, Pallor
Clinical narrative: Woke from sleep - crying then became limp, pale, quiet. cont. pale, hyporesponsive, grunting. Called 911.
Age: 77.0
Sex: F
Vaccine: TD
Symptoms: Injection site reaction, Rash erythematous
Clinical narrative: Red rash 8 in X 4 in noticed by pt 4/14/10 on pt's upper outer left arm.  TD was given 4/7/10 in pt's left deltoid.  Erythematous area was outlined & pt instructed to apply hydrocortisone cream & call back if worsening.
Age: 14.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Abasia, Fatigue, Feeling abnormal, Muscular weakness, Wheelchair user
Clinical narrative: After being given a DEXAMETHASONE shot for his asthma he became tired and began to complain of feeling not quite right. So he went to bed the next morning he was able to breathe better but as he said the night before he felt not right and now his legs had begun to hurt and became weak - so weak and painful he could not walk. Took him to ER. They did neuro exam and blood work. Sent him home. Then I contacted the study coordinator both he and his brother are in and the Dr. put him in hospital. They only did blood work again and basic neuro exam.  Checked on his asthma and had a physical therapist help him with his legs. Today he still has pain to the touch, he can not bare to stand on them because of the pain - So he is in a wheel chair. We do not know what is wrong with him! Like his brother.
Age: 1.05
Sex: M
Vaccine: HEPA, MMR, VARCEL
Symptoms: Varicella, Varicella post vaccine
Clinical narrative: Had chicken pox after inj.
Age: 15.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Activities of daily living impaired, Discomfort, Hyperaesthesia, Injection site swelling, Insomnia
Clinical narrative: Patient complained of swelling under arm pits, around toward back and shoulders. Had trouble sleeping because it was "uncomfortable" at first. Then it became painful to the touch all over shoulders, upper arms, under arms became swollen and he could not/and cannot raise arms above head without extreme pain/weakness set in also. He has been this way for the past 3 months. He goes to physical therapy so he does not become "frozen" as the neurologist describes. But the pain and weakness remain. Like his brother, he does not sleep well. And he does not go to school anymore because he cannot carry a backpack, and he fears some bumping into him. He will be redoing his 10th grade year (Hopefully).
Age: 15.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Lymphadenopathy, Muscular weakness, Pain, Pain in extremity
Clinical narrative: Patient complained of swelling under arm pits, around toward back and shoulders. Had trouble sleeping because it was "uncomfortable" at first. Then it became painful to the touch all over shoulders, upper arms, under arms became swollen and he could not/and cannot raise arms above head without extreme pain/weakness set in also. He has been this way for the past 3 months. He goes to physical therapy so he does not become "frozen" as the neurologist describes. But the pain and weakness remain. Like his brother, he does not sleep well. And he does not go to school anymore because he cannot carry a backpack, and he fears some bumping into him. He will be redoing his 10th grade year (Hopefully).
Age: 11.0
Sex: M
Vaccine: MNQ, TDAP
Symptoms: Bordetella test positive, Pertussis
Clinical narrative: Pt received TDAP 4/27/09 and tested positive PCR for Pertussis on 3/04/10.
Age: 1.0
Sex: M
Vaccine: HEPA
Symptoms: Herpes zoster
Clinical narrative: Shingles.
Age: 52.0
Sex: F
Vaccine: HEP
Symptoms: Uveitis
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #4 of 32, a 52 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 52 year old female on an unspecified date was vaccinated with her first dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. One day after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327, 1004USA02328, WAES # 1004USA02330 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 11.0
Sex: F
Vaccine: HEPA, MEN, TDAP
Symptoms: Blood calcium normal, Blood chloride normal, Blood creatinine normal, Blood potassium decreased, Blood sodium normal
Clinical narrative: Gave pt ordered vaccines, Tdap (RVL), then HAV (Rthigh)-noted needle was 5/8" on meningicoccal vaccine syringe, left exam room w/pt calm color good, sitting up; returned to exam room w/1" needle on syringe for IM injection of meningicoccal vaccine cleaned area on LVL to give vaccine. Pt asked why skin was being cleaned-explained this was giving vaccine. Pt then abruptly slumped to left, appeared to be losing consciousness. With mom's assist, laid pt on back on table, was lifting legs, when pt stiffened and began posturing, turning to the right side. Called for assist from Dr. and other staff members. pt then became incontinent of urine. The Dr. responded and was back in room; left room to call for 911 as per Dr., and had LPN stand in room w/Dr should assist be needed. Returned to room after calling 911, where pt was alert and talking quietly w/Dr and mom. Pt asked if I was going to give vaccine; advised her that this vaccine had already been given. Stayed in room until pt was under care of EMS.
Age: 11.0
Sex: F
Vaccine: HEPA, MEN, TDAP
Symptoms: Blood urea normal, Drug screen negative, Electrocardiogram normal, Haematocrit normal, Haemoglobin normal
Clinical narrative: Gave pt ordered vaccines, Tdap (RVL), then HAV (Rthigh)-noted needle was 5/8" on meningicoccal vaccine syringe, left exam room w/pt calm color good, sitting up; returned to exam room w/1" needle on syringe for IM injection of meningicoccal vaccine cleaned area on LVL to give vaccine. Pt asked why skin was being cleaned-explained this was giving vaccine. Pt then abruptly slumped to left, appeared to be losing consciousness. With mom's assist, laid pt on back on table, was lifting legs, when pt stiffened and began posturing, turning to the right side. Called for assist from Dr. and other staff members. pt then became incontinent of urine. The Dr. responded and was back in room; left room to call for 911 as per Dr., and had LPN stand in room w/Dr should assist be needed. Returned to room after calling 911, where pt was alert and talking quietly w/Dr and mom. Pt asked if I was going to give vaccine; advised her that this vaccine had already been given. Stayed in room until pt was under care of EMS.
Age: 11.0
Sex: F
Vaccine: HEPA, MEN, TDAP
Symptoms: Loss of consciousness, Musculoskeletal stiffness, Platelet count normal, Posture abnormal, Posturing
Clinical narrative: Gave pt ordered vaccines, Tdap (RVL), then HAV (Rthigh)-noted needle was 5/8" on meningicoccal vaccine syringe, left exam room w/pt calm color good, sitting up; returned to exam room w/1" needle on syringe for IM injection of meningicoccal vaccine cleaned area on LVL to give vaccine. Pt asked why skin was being cleaned-explained this was giving vaccine. Pt then abruptly slumped to left, appeared to be losing consciousness. With mom's assist, laid pt on back on table, was lifting legs, when pt stiffened and began posturing, turning to the right side. Called for assist from Dr. and other staff members. pt then became incontinent of urine. The Dr. responded and was back in room; left room to call for 911 as per Dr., and had LPN stand in room w/Dr should assist be needed. Returned to room after calling 911, where pt was alert and talking quietly w/Dr and mom. Pt asked if I was going to give vaccine; advised her that this vaccine had already been given. Stayed in room until pt was under care of EMS.
Age: 11.0
Sex: F
Vaccine: HEPA, MEN, TDAP
Symptoms: Urinary incontinence, Urine analysis normal, White blood cell count decreased
Clinical narrative: Gave pt ordered vaccines, Tdap (RVL), then HAV (Rthigh)-noted needle was 5/8" on meningicoccal vaccine syringe, left exam room w/pt calm color good, sitting up; returned to exam room w/1" needle on syringe for IM injection of meningicoccal vaccine cleaned area on LVL to give vaccine. Pt asked why skin was being cleaned-explained this was giving vaccine. Pt then abruptly slumped to left, appeared to be losing consciousness. With mom's assist, laid pt on back on table, was lifting legs, when pt stiffened and began posturing, turning to the right side. Called for assist from Dr. and other staff members. pt then became incontinent of urine. The Dr. responded and was back in room; left room to call for 911 as per Dr., and had LPN stand in room w/Dr should assist be needed. Returned to room after calling 911, where pt was alert and talking quietly w/Dr and mom. Pt asked if I was going to give vaccine; advised her that this vaccine had already been given. Stayed in room until pt was under care of EMS.
Age: 29.0
Sex: M
Vaccine: HEP
Symptoms: Uveitis
Clinical narrative: Information has been received from a published article. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #3 of 32, a 29 year old male. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 29 year old male on an unspecified date was vaccinated with his first dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. Ten days after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced symptoms of posterior uveitis. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327, WAES # 1004USA02329 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 36.0
Sex: F
Vaccine: HEP
Symptoms: Arthritis, Optic neuritis, Uveitis
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #2 of 32, a 36 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 36 year old female on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (lot number, route and site not reported). Concomitant therapy included levothyroxine sodium. On an unspecified date, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced symptoms of arthritis, optic neuritis. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02328 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 35.0
Sex: F
Vaccine: HEP
Symptoms: Arthralgia, Arthritis, Influenza like illness, Uveitis, Vaccine positive rechallenge
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #5 of 32, a 35 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 35 year old female on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. On an unspecified date after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced influenza-like symptoms, symptoms of arthritis and arthralgia. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327, WAES # 1004USA02328, WAES # 1004USA02329, WAES # 1004USA02331 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 39.0
Sex: M
Vaccine: HEP
Symptoms: Uveitis
Clinical narrative: Information has been received from a published article. This literature case was initially reported on 29-Mar-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported date. This report concerns patient #18 of 32, a 39 year old male. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second dose of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 39 year old male on an unspecified date was vaccinated with the third dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medications. One day after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES # 1004USA01716, WAES # 1004USA02327 to WAES # 1004USA02342, WAES # 1004USA02344 to WAES 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 16.0
Sex: F
Vaccine: HEP
Symptoms: Conjunctivitis, Keratitis, Scleritis, Skin nodule, Uveitis
Clinical narrative: Information has been received from a published article. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #19 of 32, a 16 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 16 year old female on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. On an unspecified date after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced symptoms of conjunctivitis, keratitis, sclerids and skin nodule. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327 to WAES # 1004USA02343, WAES # 1004USA02345 to WAES # 1004USA02357. A copy of the published article is attached as further documentation of the patient's experience.
Age: 28.0
Sex: F
Vaccine: HEP, TYP
Symptoms: Arthralgia, Erythema nodosum, Pyrexia, Uveitis
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #20 of 32, a 28 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 28 year old female on an unspecified date was vaccinated with the first dose of RECOMBIVAX HB (lot number, route and site not reported). Concomitant therapy included typhoid vaccine (unspecified). Seven days after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced symptoms of arthralgia, erythema nodusum and fever. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327 to WAES # 1004USA02344, WAES # 1004USA02346 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.
Age: 47.0
Sex: F
Vaccine: HEP
Symptoms: Retinopathy, Uveitis
Clinical narrative: Information has been received from a published article, title as stated above. This literature case was initially reported on 29-MAR-2010. This article concerned 32 patient's (8 male and 24 female) aged between one to 57 years (mean age of patients was 29 years). The patients received a RECOMBIVAX HB, manufacturer, batch number, route and site not reported, on unreported dates. This report concerns patient #21 of 32, a 47 year old female. On an unreported date between 1982 and 2009, one to fifteen days post vaccination, the patient experienced uveitis (mean time to onset of three days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in three patients and after the third vaccination in three patients. The duration of the uveitis was not reported for nine patients. One patient had recurrent uveitis after the first and second doses of vaccine. One patient had recurrent uveitis after both the second and third doses. Patient outcome had not been reported. A 47 year old female on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (lot number, route and site not reported). There was no concomitant medication. On an unspecified date after vaccination, the patient developed uveitis. At the time of the report, the patient's outcome was not reported. The patient also experienced symptoms of retinopathy. The authors stated the RECOMBIVAX HB may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms. Uveitis was considered to be an other important medical event. Other business partner numbers include E2010-02312. Additional information has been requested. The article also discussed the experience of an additional 31 patients while on therapy with RECOMBIVAX HB (WAES #1004USA01716, WAES # 1004USA02327 to WAES # 1004USA02345, WAES # 1004USA02347 to WAES # 1004USA02357). A copy of the published article is attached as further documentation of the patient's experience.